Khiron Life Sciences Corp. KHRNF KHRN A released its financial results for the year ended and quarter ended December 31, 2021.
2021 Financial Highlights:
-
Net loss of CA$33.13 million ($25.67 million) compared to net loss of CA$24,04 million in 2020, an unfavorable increase of 37.81%.
-
Revenue of CA$12.8 million compared to CA$8.02 million in 2020
-
Adjusted EBITDA was a loss of CA$17.38 million compared to a loss of CA$18.76 million in 2020.
-
Gross profit before fair value adjustments was CA$4.91 million compared to CA$1.48 million in 2020, a favorable increase of 231.75%.
Q4 2021 Financial Highlights:
-
Net loss of CA$19.5 million compared to net loss of CA$2.37 million in Q4 2020, an unfavorable increase of 722.78%.
-
Revenue of CA$3.63 million compared to CA$2.52 million in Q4 2020
-
Adjusted EBITDA was a loss of CA$5.65 million compared to a loss of CA$4.34 million in Q4 2020.
-
Gross profit before fair value adjustments was CA$1.08 million compared to CA$402,000 in Q4 2020.
Related News
Khiron Opens New Zerenia Clinic And Medical Cannabis Pharmacy In Colombia
How Efficient Is Medicinal Cannabis As Treatment For Chronic Pain? Khiron's Clinical Study Reveals
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.